Earnings Feed
Start Free
Home/Filings/4/0001232524-12-000048
4//SEC Filing

Gamble Carol A 4

Accession 0001232524-12-000048

CIK 0001232524other
View on SEC.govCompany Profile

Filed

Jan 17, 7:00 PM ET

Accepted

Jan 18, 9:06 PM ET

Size

21.9 KB

Accession

0001232524-12-000048

Insider Transaction Report

Form 4
Period: 2012-01-18
Jazz Pharmaceuticals plcJAZZ
Gamble Carol A
SVP, GC and Secretary
Transactions
  • Award

    Incentive Stock Option (right to buy)

    2012-01-18+2,229→ 2,229 total
    Exercise: $1.25Exp: 2019-01-20→ Ordinary Shares (2,229 underlying)
  • Award

    Ordinary Shares

    2012-01-18+82,213→ 82,213 total
  • Award

    Incentive Stock Option (right to buy)

    2012-01-18+11,579→ 11,579 total
    Exercise: $19.37Exp: 2017-02-26→ Ordinary Shares (11,579 underlying)
  • Award

    Incentive Stock Option (right to buy)

    2012-01-18+14,538→ 14,538 total
    Exercise: $15.09Exp: 2014-02-17→ Ordinary Shares (14,538 underlying)
  • Award

    Incentive Stock Option (right to buy)

    2012-01-18+4,845→ 4,845 total
    Exercise: $30.18Exp: 2014-02-17→ Ordinary Shares (4,845 underlying)
  • Award

    Incentive Stock Option (right to buy)

    2012-01-18+4,845→ 4,845 total
    Exercise: $45.27Exp: 2014-02-17→ Ordinary Shares (4,845 underlying)
  • Award

    Incentive Stock Option (right to buy)

    2012-01-18+3,752→ 3,752 total
    Exercise: $7.96Exp: 2018-05-15→ Ordinary Shares (3,752 underlying)
  • Award

    Incentive Stock Option (right to buy)

    2012-01-18+14,961→ 14,961 total
    Exercise: $11.48Exp: 2020-03-07→ Ordinary Shares (14,961 underlying)
Footnotes (8)
  • [F1]Acquisition made in connection with the conversion of securities in the merger (the "Merger") pursuant to the Agreement and Plan of Merger and Reorganization by and among the Issuer, Jaguar Merger Sub Inc., Jazz Pharmaceuticals, Inc. and Seamus Mulligan, solely in his capacity as indemnitors' representative. The effective date of the Merger is January 18, 2012. This report is being filed by the Reporting Person solely to report the acquisition of securities of the Issuer made in connection with the Merger. The Reporting Person has filed a separate Form 4 to reflect the corresponding disposition of securities of Jazz Pharmaceuticals, Inc. made in connection with the Merger.
  • [F2]Received in exchange for an equal number of shares of Jazz Pharmaceuticals, Inc. common stock in connection with the Merger. On the effective date of the Merger, the closing price of JAZZ was $47.34 per share.
  • [F3]This option vested one fourth on February 18, 2005, one eighth on August 18, 2005, and the remainder in 30 equal monthly installments thereafter.
  • [F4]This option has a vesting schedule of one third vested on February 27, 2010 and the remainder vesting in 24 equal monthly installments thereafter.
  • [F5]This option has a vesting schedule of one half vested on April 8, 2010 and the remainder vesting in 24 equal monthly installments thereafter.
  • [F6]This option has a vesting schedule of one third vested on January 21, 2010 and the remainder vesting in 24 equal monthly installments thereafter.
  • [F7]This option has a vesting schedule of one fourth vested on March 8, 2011 and the remainder vesting in 36 equal monthly installments thereafter.
  • [F8]Received in the Merger in exchange for an option to acquire the same number of shares of common stock of Jazz Pharmaceuticals, Inc. at the same exercise price and on substantially the same terms.

Documents

1 file

Issuer

Jazz Pharmaceuticals plc

CIK 0001232524

→
Entity typeother

Related Parties

1
  • filerCIK 0001397267

Filing Metadata

Form type
4
Filed
Jan 17, 7:00 PM ET
Accepted
Jan 18, 9:06 PM ET
Size
21.9 KB
View on SEC.gov